Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119. Erratum in: Diabetes Res Clin Pract. 2023;204:110945. https://doi.org/10.1016/j.diabres.2023.110945.

Fathallah N, Slim R, Larif S, Hmouda H, Ben SC. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38(12):1153–68. https://doi.org/10.1007/s40264-015-0339-z.

Article  CAS  PubMed  Google Scholar 

Jain V, Patel RK, Kapadia Z, Galiveeti S, Banerji M, Hope L. Drugs and hyperglycemia: a practical guide. Maturitas. 2017;104:80–3. https://doi.org/10.1016/j.maturitas.2017.08.006.

Article  CAS  PubMed  Google Scholar 

LaPreze J, Robinson A. Detecting and managing drug-induced diabetes. US Pharmacist. 2021;46(11):18–30.

Google Scholar 

Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–32. https://doi.org/10.1159/000365892.

Article  CAS  PubMed  Google Scholar 

Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728–9. https://doi.org/10.2337/dc06-1499.

Article  CAS  PubMed  Google Scholar 

Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12(4):358–62. https://doi.org/10.4158/EP.12.4.358.

Article  PubMed  Google Scholar 

Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18(9):540–57. https://doi.org/10.1038/s41574-022-00683-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–72. https://doi.org/10.1016/j.biocel.2013.05.036.

Article  CAS  PubMed  Google Scholar 

Xu C, He J, Jiang H, et al. Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol. 2009;23(8):1161–70. https://doi.org/10.1210/me.2008-0464.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond). 1999;96(5):513–23. https://doi.org/10.1042/cs0960513.

Article  CAS  PubMed  Google Scholar 

Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998;47(1):3–6. https://doi.org/10.1016/s0026-0495(98)90184-6.

Article  CAS  PubMed  Google Scholar 

Shah P, Kalra S, Yadav Y, et al. Management of glucocorticoid-induced hyperglycemia. Diabetes Metab Syndr Obes. 2022;23(15):1577–88. https://doi.org/10.2147/DMSO.S330253.

Article  Google Scholar 

Kulkarni S, Durham H, Glover L, et al. Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open. 2022;12(12): e061476. https://doi.org/10.1136/bmjopen-2022-061476.

Article  PubMed  PubMed Central  Google Scholar 

Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6. https://doi.org/10.1016/j.amjmed.2010.06.019.

Article  CAS  PubMed  Google Scholar 

Choudhry MN, Malik RA, Charalambous CP. Blood glucose levels following intra-articular steroid injections in patients with diabetes: a systematic review. JBJS Rev. 2016;4(3):e5. https://doi.org/10.2106/JBJS.RVW.O.00029.

Article  PubMed  Google Scholar 

Andersen YMF, Egeberg A, Ban L, et al. Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. Diabetes Care. 2019;42(6):1095–103. https://doi.org/10.2337/dc18-2158.

Article  CAS  PubMed  Google Scholar 

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81. https://doi.org/10.4239/wjd.v6.i8.1073.

Article  PubMed  PubMed Central  Google Scholar 

Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021;10(10):2154. https://doi.org/10.3390/jcm10102154.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yata Y, Hosojima M, Kabasawa H, et al. The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring. Intern Med. 2017;56(19):2555–62. https://doi.org/10.2169/internalmedicine.8296-16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerards MC, Venema GE, Patberg KW, et al. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab. 2018;20(5):1306–1310. https://doi.org/10.1111/dom.13209.

Appendix 8 - Sick-day medication list. Canadian J Diabetes. 2018;42(1):S316. https://doi.org/10.1016/j.jcjd.2017.10.045.

James J, Roberts A, Dhatariya K. Joint British Diabetes Societies for inpatient Care: management of hyperglycemia and steroid (glucocorticoid) therapy. Jan 2023. https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_08_Management_of_Hyperglycaemia_and_Steroid_(Glucocorticoid)_Therapy_with_QR_code_January_2023.pdf. Accessed 30 June 2024.

Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50.

Article  PubMed  PubMed Central  Google Scholar 

Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–71. https://doi.org/10.1192/bjp.bp.109.076935.

Article  PubMed  Google Scholar 

Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiat. 2013;70(10):1067–75. https://doi.org/10.1001/jamapsychiatry.2013.2053.

Article  Google Scholar 

Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):1–4. https://doi.org/10.1016/j.pnpbp.2009.11.009.

Article  CAS  PubMed  Google Scholar 

Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(Suppl 27):15–26; discussion 40–1.

Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci. 2017;21(11):643. https://doi.org/10.3389/fnins.2017.00643.

Article  Google Scholar 

Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry. 2005;10(12):1089–96. https://doi.org/10.1038/sj.mp.4001729.

Article  CAS  PubMed  Google Scholar 

Han M, Deng C, Burne TH, Newell KA, Huang XF. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569–80. https://doi.org/10.1016/j.psyneuen.2008.01.018.

Article  CAS  PubMed  Google Scholar 

Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27–35. https://doi.org/10.1038/sj.mp.4002066.

Article  CAS  PubMed  Google Scholar 

Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368–78. https://doi.org/10.2133/dmpk.20.368.